Oragenics (OGEN) Interest & Investment Income (2010 - 2026)
Oragenics' (OGEN) quarterly Interest & Investment Income came in at $40876.0 in Q1 2026, up 300.63% YoY from $10203.0 in Q1 2025, and down 53.07% on a QoQ basis from $87091.0 in Q4 2025.
Oragenics (OGEN) Interest & Investment Income (2010 - 2026) Analysis & Trends
Oragenics (OGEN) has 17 years of Interest & Investment Income data on file, last reported at $40876.0 in Q1 2026.
- Quarterly Interest & Investment Income rose 300.63% year-over-year to $40876.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $212902.0 (up 477.52% YoY) and the FY2025 annual result came in at $182229.0, up 297.04% from the prior year.
- Interest & Investment Income fell to $40876.0 in Q1 2026, from $87091.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $87091.0 in Q4 2025 to a low of $6405.0 in Q2 2024.
- A 5-year average of $36193.9 and a median of $38626.0 in 2023 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2024 — Interest & Investment Income tumbled 89.14% — and 2025, when it jumped 707.07%.
- Tracing OGEN's Interest & Investment Income over 5 years: stood at $66991.0 in 2022, then slumped by 42.34% to $38626.0 in 2023, then slumped by 72.06% to $10791.0 in 2024, then jumped by 707.07% to $87091.0 in 2025, then slumped by 53.07% to $40876.0 in 2026.
- The last three Interest & Investment Income figures came in at $40876.0 (Q1 2026), $87091.0 (Q4 2025), and $68142.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Oragenics | 2.31 Mn | 2.31 Mn | - | 30,026.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30,026.00 |
| Mar 31, 2026 | 40,876.00 |
| Dec 31, 2025 | 87,091.00 |
| Sep 30, 2025 | 68,142.00 |
| Jun 30, 2025 | 16,793.00 |
| Mar 31, 2025 | 10,203.00 |
| Dec 31, 2024 | 10,791.00 |
| Sep 30, 2024 | 9,466.00 |
| Jun 30, 2024 | 6,405.00 |
| Mar 31, 2024 | 19,235.00 |
| Dec 31, 2023 | 38,626.00 |
| Sep 30, 2023 | 50,613.00 |
| Jun 30, 2023 | 58,954.00 |
| Mar 31, 2023 | 62,201.00 |
| Dec 31, 2022 | 66,991.00 |
| Sep 30, 2022 | 41,634.00 |
| Jun 30, 2022 | 15,369.00 |
| Mar 31, 2022 | 11,906.00 |
| Dec 31, 2021 | 13,800.00 |
| Sep 30, 2021 | 17,760.00 |